Cabozantinib after progression of kidney cancer improves survival

In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed.

Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had intermediate–poor risk cancer.

Patients continuing with cabozantinib had a higher response rate to the treatment than before their cancer progressed (46.7% vs 25%) and were more heavily pretreated. Continuing cabozantinib after their cancer had progressed was associated with longer survival compared with changing treatment (average post-progression survival was 16.9 vs 13.2 months).

In this study the researchers observed longer post-progression survival in patients continuing cabozantinib after their cancer had progressed, suggesting that this could be an effective treatment option.

Read more in Practice Update here

Share this Post!

Related post